Intellia Therapeutics Stock Price Prediction
| NTLA Stock | USD 13.80 0.68 5.18% |
Oversold Vs Overbought
45
Oversold | Overbought |
EPS Estimate Next Quarter (1.42) | EPS Estimate Current Year (5.28) | EPS Estimate Next Year (5.47) | Wall Street Target Price 59.7793 | EPS Estimate Current Quarter (1.38) |
Using Intellia Therapeutics hype-based prediction, you can estimate the value of Intellia Therapeutics from the perspective of Intellia Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
Intellia Therapeutics Hype to Price Pattern
Investor biases related to Intellia Therapeutics' public news can be used to forecast risks associated with an investment in Intellia. The trend in average sentiment can be used to explain how an investor holding Intellia can time the market purely based on public headlines and social activities around Intellia Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Intellia Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Intellia Therapeutics.
The fear of missing out, i.e., FOMO, can cause potential investors in Intellia Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Intellia because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Intellia Therapeutics after-hype prediction price | USD 13.65 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Intellia |
Intellia Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Intellia Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Intellia Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Intellia Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Intellia Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Intellia Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Intellia Therapeutics' historical news coverage. Intellia Therapeutics' after-hype downside and upside margins for the prediction period are 9.31 and 17.99, respectively. We have considered Intellia Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Intellia Therapeutics is not too volatile at this time. Analysis and calculation of next after-hype price of Intellia Therapeutics is based on 3 months time horizon.
Intellia Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Intellia Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Intellia Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Intellia Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.74 | 4.34 | 0.15 | 0.15 | 10 Events / Month | 6 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
13.80 | 13.65 | 1.09 |
|
Intellia Therapeutics Hype Timeline
Intellia Therapeutics is now traded for 13.80. The entity has historical hype elasticity of -0.15, and average elasticity to hype of competition of -0.15. Intellia is expected to decline in value after the next headline, with the price expected to drop to 13.65. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -1.09%, whereas the daily expected return is now at -0.74%. The volatility of related hype on Intellia Therapeutics is about 2162.19%, with the expected price after the next announcement by competition of 13.65. About 91.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.46. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Intellia Therapeutics recorded a loss per share of 5.45. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be in about 10 days. Check out Intellia Therapeutics Basic Forecasting Models to cross-verify your projections.Intellia Therapeutics Related Hype Analysis
Having access to credible news sources related to Intellia Therapeutics' direct competition is more important than ever and may enhance your ability to predict Intellia Therapeutics' future price movements. Getting to know how Intellia Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Intellia Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| LYRA | Lyra Therapeutics | 0.01 | 5 per month | 0.00 | (0.13) | 8.00 | (10.00) | 41.07 | |
| HOOK | Hookipa Pharma | (0.05) | 6 per month | 0.00 | (0.33) | 4.05 | (7.24) | 15.72 | |
| CINGW | Cingulate Warrants | 0.01 | 1 per month | 0.00 | (0.03) | 34.83 | (25.20) | 92.13 | |
| SABS | SAB Biotherapeutics | (0.39) | 8 per month | 6.39 | 0.05 | 17.06 | (11.25) | 45.73 | |
| CVKD | Cadrenal Therapeutics, Common | 1.25 | 10 per month | 6.10 | 0.15 | 17.85 | (7.47) | 47.47 | |
| MNPR | Monopar Therapeutics | (2.62) | 9 per month | 7.94 | 0.13 | 15.93 | (9.50) | 653.56 | |
| SPRO | Spero Therapeutics | 0.02 | 10 per month | 0.00 | (0.12) | 3.79 | (4.58) | 14.92 | |
| CHRS | Coherus BioSciences | 0.01 | 9 per month | 4.72 | (0.02) | 7.62 | (6.94) | 26.43 | |
| IKNA | Ikena Oncology | (0.05) | 3 per month | 1.38 | (0.06) | 1.81 | (1.74) | 13.50 |
Intellia Therapeutics Additional Predictive Modules
Most predictive techniques to examine Intellia price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Intellia using various technical indicators. When you analyze Intellia charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Intellia Therapeutics Predictive Indicators
The successful prediction of Intellia Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Intellia Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Intellia Therapeutics based on analysis of Intellia Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Intellia Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Intellia Therapeutics's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 22.43 | 26.39 | 366.82 | 385.16 | PTB Ratio | 8.06 | 2.17 | 2.58 | 2.74 |
Story Coverage note for Intellia Therapeutics
The number of cover stories for Intellia Therapeutics depends on current market conditions and Intellia Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Intellia Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Intellia Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Intellia Therapeutics Short Properties
Intellia Therapeutics' future price predictability will typically decrease when Intellia Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Intellia Therapeutics often depends not only on the future outlook of the potential Intellia Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Intellia Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 88.8 M | |
| Cash And Short Term Investments | 912.2 M |
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |